|Karo Pharma AB -- USA Stock|| |
USD 4.1 4.1 9,223,372,036,855%
Member of the Board
Mr. Per Anders Johansson has served as Independent Member of the Board of Directors at Karo Bio AB since June 12 2012. He is also Chief Executive Officer and Chairman of CIMON and Chairman of the Savings bank in Karlshamn. He is Founder of the technical consulting company CIMON AB as well as Chief Financial Officer and Vice President of Ellos Nordico and the Karlshamn Group.
Age: 60 Executive Since 2012
46 86 08 60 00 http://www.karobio.com
The company has return on total asset (ROA)
of 3.4 %
which means that it generated profit of $3.4 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 15.83 %
meaning that it generated $15.83 on every $100 dollars invested by stockholders.
The company has accumulated 75.57 M in total debt with debt to equity ratio (D/E) of 59.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karo Pharma AB has Current Ratio of 2.21 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Karo Pharma AB , a pharmaceutical company, develops various drugs in Sweden. Karo Pharma AB (KARBF) is traded on OTC Market in USA. It is located in Stockholm, and employs 39 people.